Montserrat Alegret

Dr. Montserrat Alegret

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2018 in Science
Verified
Journal Article
Open access
PDF file
TCThe Brainstorm Consortium
The Brainstorm Consortium
VAVerneri Anttila
Verneri Anttila
BBBrendan Bulik-Sullivan
Brendan Bulik-Sullivan
HFHilary K. Finucane
Hilary K. Finucane
RWRaymond K. Walters
Raymond K. Walters
BNBenjamin M. Neale
Benjamin M. Neale
Brainstorming diseases: Consistent classification of neuropsychiatric diseases is problematic because it can lead to misunderstanding of etiology. The Brainstorm Consortium examined multiple genome-wide association studies drawn from more than 200,000 patients for 25 brain-associated disorders and 17 phenotypes. Broadly, it appears that psychiatric and neurologic disorders share relatively little common genetic risk. However, different and independent pathways can result in similar clinical manifestations (e.g., psychosis, which occurs in both schizophrenia and Alzheimer's disease). Schizophrenia correlated with many psychiatric disorders, whereas the immunopathological affliction Crohn's disease did not, and posttraumatic stress syndrome was also largely independent of underlying traits. Essentially, the earlier the onset of a disorder, the more inheritable it appeared to be. Science , this issue p. eaap8757

1 August 2001 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
MAMontserrat Alegret
Montserrat Alegret
CJCarme Junque
Carme Junque
FVFrancesc Valldeoriola
Francesc Valldeoriola
PVPere Vendrell
Pere Vendrell
MPManuela Pilleri
Manuela Pilleri
ETEduardo Tolosa
Eduardo Tolosa
IN THE 1990s, surgical stimulation techniques were introduced to treat patients with Parkinson disease (PD) in whom pharmacological treatment failed.1 Although there is growing evidence of the beneficial effects of chronic bilateral subthalamic deep brain stimulation (STN-DBS) on PD motor symptoms,2-7 its influence on neuropsychological functions has not yet been investigated thoroughly. Although STN-DBS does not produce a global frontal deterioration,6,8 a negative effect in specific prefrontal functions (eg, phonetic verbal fluency)8,9 and verbal and visuospatial memory9 has been described. However, reports of performance on a prefrontal measure, the Trail-Making B Test, are contradictory. Although Trépanier et al9 found poorer performance, Ardouin et al8 found improvement after STN-DBS, a discrepancy that may be due to methodological differences. For instance, in the study by Trépanier et al,9 the neuropsychological assessment was performed while patients were under the effects of levodopa, whereas in the study by Ardouin et al,8 it was performed while some patients were receiving and others were free of levodopa.

4 March 2013 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
AEAna Espinosa
Ana Espinosa
MAMontserrat Alegret
Montserrat Alegret
SVSergi Valero
Sergi Valero
GVGeorgina Vinyes-Junqué
Georgina Vinyes-Junqué
IHIsabel Hernández
Isabel Hernández
MBMercè Boada
Mercè Boada
The most recent studies about mild cognitive impairment (MCI) are focused on the search for factors that make patients more vulnerable to conversion to dementia, mainly Alzheimer's disease (AD). The aim of this study was to determine which neuropsych

6 September 2022 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
IJIris E. Jansen
Iris E. Jansen
SLSven J. van der Lee
Sven J. van der Lee
DGDuber Gomez-Fonseca
Duber Gomez-Fonseca
IRItziar de Rojas
Itziar de Rojas
MDMaria Carolina Dalmasso
Maria Carolina Dalmasso
WFWiesje van der Flier
Wiesje van der Flier
Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer’s disease (AD) more directly than clinical diagnosis. Initiated by the European Alzheimer & Dementia Biobank (EADB), the largest collaborative effort on genetics underlying CSF biomarkers was established, including 31 cohorts with a total of 13,116 individuals (discovery n = 8074; replication n = 5042 individuals). Besides the APOE locus, novel associations with two other well-established AD risk loci were observed; CR1 was shown a locus for Aβ42 and BIN1 for pTau. GMNC and C16orf95 were further identified as loci for pTau, of which the latter is novel. Clustering methods exploring the influence of all known AD risk loci on the CSF protein levels, revealed 4 biological categories suggesting multiple Aβ42 and pTau related biological pathways involved in the etiology of AD. In functional follow-up analyses, GMNC and C16orf95 both associated with lateral ventricular volume, implying an overlap in genetic etiology for tau levels and brain ventricular volume.

15 March 2016 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
ALA Lacour
A Lacour
AEA Espinosa
A Espinosa
ELE Louwersheimer
E Louwersheimer
SHS Heilmann
S Heilmann
IHI Hernández
I Hernández
ARAgustín Ruiz
Agustín Ruiz
Few data are available concerning the role of risk markers for Alzheimer’s disease (AD) in progression to AD dementia among subjects with mild cognitive impairment (MCI). We therefore investigated the role of well-known AD-associated single-nucleotide polymorphism (SNP) in the progression from MCI to AD dementia. Four independent MCI data sets were included in the analysis: (a) the German study on Aging, Cognition and Dementia in primary care patients (n=853); (b) the German Dementia Competence Network (n=812); (c) the Fundació ACE from Barcelona, Spain (n=1245); and (d) the MCI data set of the Amsterdam Dementia Cohort (n=306). The effects of single markers and combined polygenic scores were measured using Cox proportional hazards models and meta-analyses. The clusterin (CLU) locus was an independent genetic risk factor for MCI to AD progression (CLU rs9331888: hazard ratio (HR)=1.187 (1.054–1.32); P=0.0035). A polygenic score (PGS1) comprising nine established genome-wide AD risk loci predicted a small effect on the risk of MCI to AD progression in APOE-ɛ4 (apolipoprotein E-ɛ4) carriers (HR=1.746 (1.029–2.965); P=0.038). The novel AD loci reported by the International Genomics of Alzheimer's Project were not implicated in MCI to AD dementia progression. SNP-based polygenic risk scores comprising currently available AD genetic markers did not predict MCI to AD progression. We conclude that SNPs in CLU are potential markers for MCI to AD progression.

28 November 2016 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
PDF file
MBMerce Boada
Merce Boada
FAFernando Anaya
Fernando Anaya
POPilar Ortiz
Pilar Ortiz
JOJavier Olazarán
Javier Olazarán
JSJoshua R. Shua-Haim
Joshua R. Shua-Haim
APAntonio Páez
Antonio Páez
Background: Studies conducted in animal models and humans suggest the presence of a dynamic equilibrium of amyloid-β (Aβ) peptide between cerebrospinal fluid (CSF) and plasma compartments. Objective: To determine whether plasma exchange (PE) with albumin replacement was able to modify Aβ concentrations in CSF and plasma as well as to improve cognition in patients with mild-moderate Alzheimer’s disease (AD). Methods: In a multicenter, randomized, patient- and rater-blind, controlled, parallel-group, phase II study, 42 AD patients were assigned (1 : 1) to PE treatment or control (sham) groups. Treated patients received a maximum of 18 PE with 5% albumin (Albutein ® , Grifols) with three different schedules: two PE/weekly (three weeks), one PE/weekly (six weeks), and one PE/bi- weekly (12 weeks), plus a six-month follow-up period. Plasma and CSF Aβ 1–40 and Aβ 1–42 levels, as well as cognitive, functional, and behavioral measures were determined. Results: CSF Aβ 1–42 levels after the last PE compared to baseline were marginally higher in PE-treated group versus controls (adjusted means of variation: 75.3 versus –45.5 pg/mL; 95% CI: –19.8, 170.5 versus 135.1, 44.2; p = 0.072). Plasma Aβ 1–42 levels were lower in the PE-treated group after each treatment period ( p < 0.05). Plasma Aβ 1–40 levels showed a saw-tooth pattern variation associated with PE. PE-treated patients scored better in the Boston Naming Test and Semantic Verbal Fluency ( p < 0.05) throughout the study. Neuropsychiatric Inventory scores were higher in controls during the PE phase ( p < 0.05). Conclusion: PE with human albumin modified CSF and plasma Aβ 1–42 levels. Patients treated with PE showed improvement in memory and language functions, which persisted after PE was discontinued.